Compare Immunovant Inc. Common Stock (IMVT) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Rambus Inc. Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $28.35 (market cap $5.93B), while Rambus Inc. Common Stock trades at $89 (market cap $10.66B). The key difference: Rambus Inc. Common Stock is the larger of the two by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Rambus Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 6 Days and Rambus Inc. Common Stock for 0 Days on average.
| IMVT | RMBS | |
|---|---|---|
Market Cap | $5.93B | $10.66B |
Volume | 1,242,632 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $44.96 | $170.66 |
52-Week Low | $17.41 | $79.73 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.03B | $9.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Immunovant (IMVT) trades at $28.71, down 2.61% with bearish technical signals despite strong analyst support. The company shows no revenue with substantial losses (-$413.84M net income) and negative margins, though it maintains a robust cash position from recent financing. Recent clinical setbacks, including the discontinuation of IMVT-1402 for cutaneous lupus, have pressured the stock, while multiple law firm investigations into potential fiduciary breaches add uncertainty.
The investment case hinges on IMVT-1402's success in other indications like Graves' disease, with a bullish analyst consensus (78% buy ratings) contrasting high execution risks. Key risks include clinical trial outcomes, cash burn, and legal overhangs. The stock's viability depends heavily on pipeline progress against a backdrop of persistent losses and volatile sentiment.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
